Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betaprodine SCHEMBL25053 | 0.93 | LMNA (0.97) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Betaprodine SCHEMBL186644 | 0.93 | LMNA (0.97) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Betaprodine SCHEMBL248367 | 0.93 | LMNA (0.97) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Alphaprodine SCHEMBL25054 | 0.93 | LMNA (0.97) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Proheptazine SCHEMBL7618840 | 0.92 | LMNA (0.72) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Betaprodine SCHEMBL394431 | 0.91 | LMNA (1.00) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Alphaprodine SCHEMBL8818643 | 0.91 | LMNA (1.00) | LMNADRD3OPRM1OPRD1OPRK1 | |
| Betaprodine SCHEMBL1649307 | 0.90 | LMNA (0.93) | LMNADRD3OPRM1OPRD1OPRK1 | |
| SCHEMBL12369088 | 0.89 | LMNA (0.67) | LMNADRD3OPRM1OPRD1OPRK1 | |
| SCHEMBL12369092 | 0.88 | LMNA (0.65) | LMNADRD3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3512 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-12036192-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2024-07-16 | — | — | US | claimed |
| US-11964056-B1 | Tamper resistant dosage forms | PURDUE PHARMA L.P (US) | 2024-04-23 | — | — | US | claimed |
| US-20020032581-A1 | Single-patient drug trials used with accumulated database: risk of habituation | OPT-E-SCRIP, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002006826-A1 | SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE | OPT-E-SCRIP, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| US-6335033-B2 | SUSTAINED RELEASE | EURO-CELTIQUE, S.A. (LU) | 2002-01-01 | — | — | US | claimed |
| WO-2001080797-A1 | MEDICATED WRAP | HYSON MORTON I (US) | 2001-11-01 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5965161-A | SUSTAINED RELEASE ORAL UNIT DOSAGE FORM COMPRISING EXTRUDED NON-SPHEROIDAL PARTICLES OF AN OPIOID ANALGESIC IN A MATRIX OF RETARDANT(S) AND A WATER INSOLUBLE BINDER FORMED BY MIXING IN AN EXTRUDER, AND CUTTING EXTRUDED STRANDS INTO PARTICLES | EURO-CELTIQUE, S.A. (LU) | 1999-10-12 | — | — | US | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |